ClinicalTrials.gg
Not yet recruitingNCT07647133Updated Jun 15, 2026

A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Chronic Kidney Disease

A Phase 2 interventional study of SAL0140 Tablets and SAL0140 Tablets in Chronic Kidney Disease, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
249
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 245 studies in Renal Insufficiency, Chronic with a site in China — 94 open to participants now, 107 under way, 17 of them phase 3. Renal Insufficiency, Chronic · China.

Planned enrollment
70th of 164
249 · median 182
Started
2026
with 26 others
Phase 2
22 of 245
5 open now
Primary completion
2027-10
later than 61 of 106 live
Registered
232nd of 245
by date

Among the 245 studies in Renal Insufficiency, Chronic with a site in China, this one is the 70th largest by planned enrollment of the 164 interventional ones that give a count, is one of 27 that started in 2026, is one of 22 in phase 2, reaches primary completion later than 61 of the 106 other live ones, and was the 232nd registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

94 of the 245 studies in Renal Insufficiency, Chronic with a site in China are open now. Recruiting first, the newest first:

89 more — sign in →

All 94 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 245 studies in Renal Insufficiency, Chronic with a site in China, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of SAL0140 in patients with chronic kidney disease (CKD).

Read the detailed description

This is a multicenter, randomized, double-blind, placebo-controlled phase II study designed to explore the efficacy and safety of multiple doses of SAL0140 in patients with chronic kidney disease (CKD). 249 participants diagnosed with chronic kidney disease will be randomized in a 1:1:1 ratio into 1 of the 3 treatment groups (placebo, low dose treatment strategy and high dose treatment strategy).

The study will consist of the following 4 periods: screening period, run-in period, double-blind treatment period and follow-up period. Patients will complete the study in approximately 8 months.

03

Conditions studied

  • Chronic Kidney Disease

Keywords

  • Chronic Kidney Disease
  • Aldosterone Synthase Inhibitor
  • Renin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥18 years , regardless of gender.
  2. Diagnosed with chronic kidney disease (CKD)
  3. Urine albumin-creatinine ratio (UACR) of ≥300 mg/g and ≤5000 mg/g.
  4. Serum potassium≥ lower limit of normal (LLN) and ≤4.8 mmol/L.
  5. Receiving stable background concomitant medication at screening
  6. Mean seated office systolic blood pressure (msSBP) ≥120 mmHg.
  7. Morning serum cortisol >3 μg/dL.
  8. Voluntarily participate in the trial and provide written .
  9. Agree to comply with trial and reproductive restrictions.

Exclusion criteria

Exclusion Criteria:

  1. Had a documented diagnosis of autosomal dominant polycystic kidney disease or chronic kidney disease associated with infection or .
  2. Had acute kidney injury or end-stage renal disease, received peritoneal dialysis, hemodialysis or kidney transplantation; or planned to undergo kidney transplantation or chronic renal replacement therapy during the study period.
  3. Mean seated office systolic blood pressure (msSBP) ≥180 mmHg and/or mean seated office diastolic blood pressure (msDBP) ≥110 mmHg. History or diagnosis of malignant hypertension, hypertensive emergency, hypertensive crisis or hypertensive encephalopathy.
  4. History or diagnostic evidence of other secondary hypertension.
  5. Serum sodium \<135 mmol/L .
  6. Subjects with severe hepatobiliary diseases.
  7. Positive test for antibody (HIV), antibody (HCV), treponema pallidum antibody (TP), or positive surface antigen (HBsAg).
  8. Receiving blood transfusion for anemia.
  9. Poorly controlled diabetes mellitus.
  10. Morbid obesity.
  11. Had cardiovascular disease that precludes participation in the study or any (ECG) abnormalities deemed by the investigator to substantially increase the subject's risk.
  12. History of adrenal insufficiency.
  13. History of solid organ or bone marrow transplantation.
  14. Medication compliance \<80% or >120%.
  15. History of acute diabetic complications.
  16. Prior exposure to rituximab or cytotoxic chemotherapeutic agents.
  17. Prior exposure to systemic drugs.
  18. Recent use of traditional Chinese medicine (TCM) or proprietary Chinese preparations indicated for urinary protein reduction.
  19. Recent use of strong inhibitors or CYP3A inducers.
  20. Active malignancy or past medical history of malignant tumor.
  21. Gastrointestinal disorders or prior gastrointestinal surgery that may affect drug absorption or excretion.
  22. History of substance abuse or chronic alcohol abuse.
  23. Recent blood donation or major blood loss (>400 mL), or clinically diagnosed hypovolemia.
  24. Female subjects who are pregnant, breastfeeding, or with positive pregnancy test result.
  25. Participation in any other clinical trial and receipt of an product within 3 months.
  26. Presence of , unstable or uncontrolled concomitant diseases as assessed by the Investigator at screening.
  27. Any other conditions judged by the Investigator to render the subject unsuitable for trial participation and likely to confound efficacy and/or safety assessment.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
249 participants (estimated)

Study arms

  • Experimental
    Low-dose group

    Drug: SAL0140 Tablets

  • Experimental
    High-dose group

    Drug: SAL0140 Tablets

  • Placebo comparator
    Placebo group

    Drug: SAL0140 placebo

Interventions

06

What researchers measure

Primary outcomes

  1. The baseline change of UACR

    Change from baseline in UACR compared to placebo at Week 16

    Time frame: at week 16

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Oct 2027, 15 months later.

Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's planned 15 months is below that.

Counting every sponsor, half of 139 studies reached it within 25 months; a quarter within 15 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2026
First posted
Jun 15, 2026
StartEst.
Jun 15, 2026
Primary completionEst.
Oct 8, 2027
CompletionEst.
Dec 31, 2027
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07647133
Responsible party
Sponsor
First posted
Jun 15, 2026
Start date
Jun 15, 2026 (estimated)
Primary completion
Oct 8, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jun 15, 2026

Study contacts

Zhihong Liu, Master
Contact
zhliunj@vip.163.com
025-80862013
Zhen Liang, PhD
Contact
sunylz@163.com
13798304368

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SAL0140

Start the discussion